CDSCO vs FDA regulatory requirements are no longer a choice for Indian medical device manufacturers that plan to expand beyond the domestic markets. India and the United States are two highly contrasting yet equally relevant regulatory environments, both with their own approval pathways, compliance expectations, and enforcement practices.
In India, the medical devices are controlled by the Central Drugs Standard Control Organization (CDSCO), and to provide entry into the U.S. market, one has to agree with the U.S. Food and Drug Administration (FDA). Even though the two regulators are risk-based in their approach, the documentation, clinical evidence, post-market controls, and rigor of inspection differ greatly.
The comparison of approvals is not just in the case of Indian manufacturers, particularly the manufacturers of software-enabled, connected or digital medical devices. Both CDSCO and FDA now require vigorous cybersecurity controls, such as vulnerability checks and penetration testing, as part of product safety and lifecycle management.
This manual will present a very useful India CDSCO vs US FDA comparison to help manufacturers to know the main regulatory differences, approval procedures, and compliance plans to succeed in the two different markets.
What Is CDSCO?
The Central Drugs Standard Control Organization is the national regulatory body of India that regulates drugs, diagnostics, cosmetics, and medical devices under the Ministry of Health and Family Welfare. As an Indian manufacturer, CDSCO is the most important regulator in terms of market access in the domestic market, and in most cases, it is the initial regulator before seeking approval in the foreign market, like the United States.
What Indian Manufacturers Should Understand About CDSCO
- Regulation Under Medical Device Rules (MDR), 2017: CDSCO has oversight of the medical devices in the form of the Medical Device Rules, 2017, which formally identify the medical devices and set the standards of the classification, licensing, quality system, clinical examination, labeling, and post-market follow-up. These regulations bring India closer to the international standards of medical devices.
- Risk-Based Classification System: CDSCO adheres to a risk-based approach, where regulatory examinations become more general with the risk presented by the device:
- Class A and Class B: Low/moderate risk devices, which include non-invasive equipment or simple diagnostic equipment. These are usually associated with less complicated documentation and speedy approval processes.
- Class C and Class D: Moderate to high-risk, such as implantable devices and life-supporting devices, which need a considerable amount of technical review, clinical justification, and central regulatory oversight.
- Approval Authority Scales With Device Risk: The central CDSCO assumes state licensing authorities in the role of approval authority as device risk increases. High-risk devices are directly checked on the national level to make sure that they are consistent and safe for the patient.
- Oversight of Domestic Manufacturing and Imports: CDSCO applies the same to locally produced and imported medical devices. The importers should have the presence of the authorized agents in India, and the overseas manufacturing facilities must meet the Indian regulations, quality and documentation standards.
CDSCO Medical Device Approval Process (High Level)
- Applicability and Classification Assessment: Under MDR 2017, manufacturers need to be able to identify which of their products should be considered a medical device and the appropriate risk category, which determines the complexity of the approval and scheduling.
- Submission of Device Master File (DMF) and Plant Master File (PMF)
- DMF contains a lot of information about a product: intended use, design, materials, performance, classification as risky, and safety data.
- PMF also provides the details of manufacturing sites, quality control, manufacturing processes, layout of the facilities, and compliance.
- Quality System Compliance (ISO 13485): Compliance with ISO 13485 is also expected of manufacturers and normally shows that a strong quality management system is established to achieve reliable product safety and performance.
- Clinical Evidence (Where Required): CSDCO might be in need of clinical investigation data or performance evaluation reports, depending on the type of device, novelty, and the risk classification. Devices of lower risk or that are well established can qualify to be waived.
- Manufacturing or Import Licensing: When CDSCO inspects successfully, licenses are granted to the manufacture or importation of medical devices in India, provided that compliance is maintained and inspections are conducted on a periodical basis.
Growing Focus Areas Under CDSCO
- Software-Enabled and Connected Medical Devices: The rise of digital health technologies is reflected in CDSCO in the intensification of the inspection of the devices that are based on software, mobile apps, cloud platforms, or network connectivity.
- Post-Market Surveillance and Vigilance: Regulatory focus is becoming more of continuous monitoring once in the market, including adverse event reporting, corrective measures and recall where needed.
- Cybersecurity and Protection Against Digital Threats: As risks of illegal access and device hacking increase, CDSCO is slowly encouraging manufacturers to deal with software safety, intrusion prevention and cybersecurity risk avoidance, especially in the case of connected medical devices.
CDSCO approval is often seen by Indian manufacturers as a prerequisite to local sales and a regulatory stage of foundation before seeking global approvals like the FDA clearance.
What Is FDA?
The regulatory body is the U.S. Food and Drug Administration (FDA), which is charged with the responsibility of ensuring safety, effectiveness and quality of the medical devices sold in the United States. In the case of Indian manufacturers, a legal requirement is the FDA clearance or approval to sell or distribute medical devices in the U.S market.
FDA Medical Device Classification
The FDA classifies medical devices into three risk categories, with regulatory controls increasing progressively based on the level of risk:
- Class I – Low Risk Devices
Principal to general controls, with labeling, registration, and good manufacturing practices being the main. Numerous Class I products do not require premarket filing. - Class II – Moderate Risk Devices
Entail general controls with special controls, including performance standards, post-market surveillance, and, in the vast majority of cases, a 510 (k) filing. - Class III – High Risk Devices
Apparatus which promotes or maintains life or poses danger. These need the strictest examination under Premarket Approval (PMA) with the help of a lot of clinical and technical information.
FDA Medical Device Approval Process (High Level)
- Establishment Registration and Device Listing
The manufacturers and the facilities are required to comply with the FDA by registering and listing their medical devices once a year. - Selection of Appropriate Premarket Pathway
- 510(k): Shows substantial similarity to a predicate device that was successfully brought to the market.
- De novo: When the devices are new, moderate risk, and there is no predicate.
- PMA: needed in case of high-risk Class III machines.
- Submission of Comprehensive Technical and Clinical Documentation
FDA would require in-depth documentation, which includes design controls, risk management, verification and validation, software documentation and clinical or performance evidence. - FDA Review, Queries, and Inspections
The FDA can impose deficiency questions, demand extra data and perform foreign facility inspections to ensure compliance, and before giving clearance or approval.
Key Focus Areas for Indian Manufacturers Under FDA
- Strong Emphasis on Design Controls and Risk Management
FDA tries to inspect design history files, usability engineering, and risk analysis during the lifecycle of the device. - Mandatory Post-Market Surveillance and Reporting
Manufacturers need to adhere to constant requirements which include reporting of adverse events, recalls, and real-life performance. - Intensive Review of Software and Cybersecurity
There is a high scrutiny on software performance, cycle records of the software lifecycle and the risk management of cybersecurity. - Cybersecurity Testing for SaMD and Connected Devices
FDA is placing more and more expectations on vulnerability testing and penetration testing of Software as a Medical Device (SaMD) and related connected medical devices.
All in all, the FDA is subject to greater technical examination and lifecycle control as compared to CDSCO. Consequently, Indian manufacturers who are aiming at the U.S. market have to plan early regulations.
Must read: Selecting the Right Cybersecurity Partner for Your FDA Submission
CDSCO vs FDA Regulatory Requirements Overview
The regulatory philosophy between the CDSCO of India and the FDA of the United States is essential when an Indian manufacturer of medical equipment intends to establish its products domestically and also enter the U.S. market. Although both regulators use a risk-based approach, their expectations, documentation depth, enforcement rigor and lifecycle oversight models vary widely. Prior knowledge of these disparities assists manufacturers in developing effective approval plans, minimize rework, as well as guarantee compliance in the long term.
Regulatory Approach
- CDSCO Regulatory Model: Central Drugs Standard Control Organization (CDSCO) mainly deals with the authorization of markets via licensing under the Medical Device Rules (MDR), 2017. It has a regulatory environment that focuses on standards compliance, licensure, and quality system certification and is increasingly moving towards international conformity.
- FDA Regulatory Model: The U.S. Food and Drug Administration (FDA) focuses on pre market clearance or approval that is backed by substantial technical, clinical or post-market evidence. The FDA regulation goes far beyond the initial approval and provides a lifecycle inspection, surveillance, and corrective measures.
Risk-Based Classification
- Shared Risk-Based Philosophy: Medical devices are categorized into different levels of risk by both CDSCO and FDA, and the more risks a device has, the more intense control over it.
- Depth of Review Differs: Although both regulators raise the requirements when risks are on the increase, the FDA tends to impose a more thorough technical examination in all risk categories, such as software validation, usability engineering, and cybersecurity risk assessment, even in the moderate risk category of devices.
Compliance Philosophy
- CDSCO Compliance Expectations: CDSCO gives high value to quality system certification, conformity assessment and adherence to established standards like ISO 13485. Compliance with regulations tends to be proved with the help of systematic documents and evidence certification.
- FDA Lifecycle Compliance Model
This implies that FDA anticipates lifecycle compliance across the end-to-end lifecycle of the device, which includes:- Design controls and design history files.
- Risk management and usability engineering.
- Performance in the real world and post-market data.
- Continuous monitoring and mitigation of cybersecurity.
- Maintaining compliance is not fixed, and it has to be actively sustained once entered into the market.
Cybersecurity as a Common Requirement
- Converging Expectations: Cybersecurity is now considered by both CDSCO and FDA as an essential element of the safety of medical devices, especially software-enabled and connected, and cloud-integrated devices.
- Regulatory Expectations in Practice
Manufacturers are more and more expected to show:- Identification and mitigation of vulnerability.
- Secure software development lifecycle.
- Penetration testing and threat modeling.
- Cybersecurity surveillance after the market.
These similar expectations underscore the necessity of a direct CDSCO vs FDA comparison among Indian manufacturers intending on doing parallel approvals in India and the U.S.
CDSCO vs FDA: Key Differences for Indian Manufacturers
As much as both CDSCO and FDA regulate medical equipment through a risk-based approach, their compliance requirements and enforcement vehicles vary significantly. The knowledge of these differences enables Indian manufacturers to avoid wastage of time, rejection of regulatory approvals, and to streamline approvals sequencing.
Regulatory Scope and Enforcement
- CDSCO Enforcement Scope: CDSCO mainly regulates those within India, which are mostly domestic manufacturing sites, importers and agents authorized to operate in the Indian market.
- FDA Global Enforcement Authority: Even where the production facility is not located in the United States, FDA has the ability to exercise and take action against any foreign manufacturer using means like import alerts, warning letters, and market prohibitions.
Approval Timelines
- CDSCO Timelines: The process of approval in CDSCO is less predictable and has shorter approval timelines, especially for low and moderate-risk devices.
- FDA Timelines: Timelines in the FDA review are more variable and longer and depend on the quality of submissions, novelty of the device, clinical information requested, and the premarket pathway chosen (510(k), De Novo, or PMA).
Documentation Depth
- CDSCO Documentation Style: CDSCO depends a lot on certifications, conformity tests, and summary technical documentation, such as DMF and PMF submissions.
- FDA Documentation Expectations
FDA expects voluminous, product related documentation, such as:- Design controls and design history files.
- Checking of and validation reports.
- Software documentation and risk analysis.
- Evidence of cybersecurity risks management.
Clinical Evidence Requirements
- CDSCO Clinical Expectations: CDSCO may either renounce or restrict clinical trials of some types of devices, particularly those that are well established or less risky.
- FDA Clinical Rigor: FDA also often demands strong clinical or performance data, especially in new technologies, software-driven devices and products with higher risks.
Post-Market Compliance
- CDSCO Post-Market Evolution: The post-market surveillance requirements under CDSCO are changing towards being more rigorous, and both vigilance and reporting of adverse events are becoming more and more important.
- FDA Post-Market Enforcement: FDA imposes systemized and ongoing postmarket requirements, such as compulsory adverse incident reporting, recalls, field corrections, and in reality, performance surveillance.
Cybersecurity Expectations
- CDSCO Direction: CDSCO is gradually complying with the global expectations in cybersecurity, especially for connected and software-based medical devices.
- FDA Cybersecurity Requirements
FDA explicitly expects:- A lifecycle of managing the cybersecurity risks.
- Management of vulnerability and coordinated disclosure.
- Secure update mechanisms
- SaMD and connected device penetration testing, which is frequently evaluated during submissions and inspections.
Why These Differences Matter
All these differences in CDSCO vs FDA compliance make Indian manufacturers more likely to struggle with FDA approval. A proactive look at any of the two sets of regulations, particularly those of software, connected or export-oriented devices, assists the manufacturing companies to minimize risk on approval, coordinate documentation plans, and provide expedited and environmentally friendly market entry in both the United States and India.
Suggested Read: How To Get A Product FDA Approved
CDSCO vs FDA Comparison Table (India vs US)
| Aspect | CDSCO (India) | FDA (United States) |
| Regulator | Central Drugs Standard Control Organization | U.S. Food and Drug Administration |
| Primary Goal | Market authorization through licensing | Premarket clearance or approval plus lifecycle oversight |
| Device Classification | Increasing focus on software and connected devices | Frequently more demanding, especially for novel or higher-risk devices |
| Common Approval Routes | Manufacturing License, Import License (MDR 2017) | 510(k), De Novo, PMA |
| Documentation Style | DMF, PMF, standards and conformity focused | Detailed technical file, design controls, V&V evidence |
| Quality System Expectation | Class A, B, C, D (risk-based) | QMS compliance expected (FDA quality requirements apply) |
| Clinical Evidence | Often depends on class and device type; may be lighter for some categories | Strong, explicit expectations for cybersecurity across the lifecycle |
| Inspections and Audits | Licensing linked inspections based on risk | Strong inspection culture; foreign sites can be inspected |
| Post Market Surveillance | Strengthening over time | Highly structured and strictly enforced reporting and monitoring |
| Cybersecurity Requirement | Needed for software-enabled and connected devices as part of cybersecurity assurance | Expected for SaMD and connected devices; often reviewed in submissions and post-market |
| Penetration Testing | Class I, II, III (risk-based) | Expected for SaMD and connected devices; often reviewed in submissions and post market |
This table provides a brief Indian CDSCO vs US FDA comparison and explains why it is better to plan both systems at an early stage with cybersecurity penetration testing to save on rework and regulatory risk.
CDSCO vs FDA: Cybersecurity and Penetration Testing Requirements
The growing use of medical devices based on software, wireless, and cloud-based solutions has resulted in the cybersecurity of both the Central Drugs Standard Control Organization (CDSCO) and the U.S. Food and Drug Administration (FDA) having the same regulatory priority. To the Indian manufacturers, this development is a strong indication that cybersecurity is no longer an additional technical factor. Rather, it has turned into a critical aspect of regulatory compliance both in India and the United States and is directly associated with patient safety, device reliability, and results of regulatory approval.
FDA Cybersecurity Expectations
FDA is highly concerned with the concept of secure-by-design, whereby manufacturers have to focus on cybersecurity risks at the earliest opportunity during product development. This involves the determination of possible threats, the definition of security controls and the incorporation of defenses during the software development life cycle. Manufacturers are supposed to prove that they can identify, measure and address software vulnerabilities in a proactive and methodical way.
With respect to software-driven devices, such as Software as a Medical Device (SaMD) and connected medical devices, the FDA expects the threat modelling, vulnerability testing, and penetration testing to be included in premarket submissions. Such cybersecurity activities are tested as indicators that the device is capable of overcoming real-life cyberattacks. Notably, the expectations of FDA do not cease once approval is made. Manufacturers should uphold ongoing post-market cybersecurity monitoring, have vulnerability disclosure procedures, and record cybersecurity vulnerabilities that may affect the safety or performance of a device.
CDSCO Cybersecurity Direction
The cybersecurity strategy of CDSCO is changing as the ecosystem of medical devices in India is growing digital. There is an increasing regulatory concern over the safety and reliability of software-based and connected medical devices, especially those which process patient medical data or are dependent on network connectivity. Although CDSCO guidance might not be as prescriptive as that of the FDA, the expectation is already being directed toward a global best practice of cybersecurity.
Manufacturers are also under increased pressure to provide risk-based cybersecurity controls, particularly to devices with greater risks, imported devices, and interconnected devices. This consists of managing software vulnerabilities, adopting secure design approaches, and providing post-market surveillance to cybersecurity-related threats. With CDSCO intensifying its regulatory framework, evidence of cybersecurity, such as penetration testing and software risk testing are increasingly more applicable when regulators review and conduct inspections.
Why Penetration Testing Matters for Both
Penetration testing is also important in addressing the requirements of both CDSCO and FDA concerning cybersecurity expectations. It gives empirical evidence on the actual security posture of a device in real-world settings, and manufacturers can use it to determine the areas of weakness that can be addressed once the device is implemented in clinical settings. Penetration testing before submission to regulatory authorities will enable manufacturing companies to deal with vulnerabilities constructively instead of responding to them.
Regulatively, penetration testing enhances trust in reviews and inspections since it shows that cybersecurity risks have been assessed and addressed in an orderly manner. It also aids in minimizing the risk of post-market issues, including a recall, safety communication, or enforcement action in response to a cybersecurity failure. To Indian manufacturers, who are also present on both markets, early alignment of cybersecurity strategy and penetration testing that meet the requirements of both regulators makes it easier to comply, as well as improve long-term regulatory trustworthiness.
Also Read: FDA 510(k) Compliance and Why It Matters for Medical Devices
Which Is More Challenging: CDSCO or FDA?
Most of the Indian medical device manufacturers find it more difficult to comply with the FDA than with the CDSCO. To a great extent, this can be attributed to more technical scrutiny by the FDA and the fact that regulatory compliance should be maintained during the entire lifecycle of the product and not only proved at the market entry point.
Why FDA Is Often More Demanding
FDA needs a lot of product-related technical documentation beyond certifications and summarized evidence. These involve elaborated design controls, verification and validation data, usability engineering and exhaustive risk management documentation. Regulatory reviews often take numerous processes of interrogation, and the manufacturers are supposed to answer with definite, well-informed technical reasons.
Moreover, the FDA imposes severe post-market requirements, such as adverse event reporting, recall, and real-world performance monitoring. With software-driven and connected devices, documentation and cybersecurity penetration testing of the software is raised to an even greater degree of examination, which is an oftentimes problematic area among first-time FDA applicants.
CDSCO Challenges to Consider
Though approval by CDSCO is seen to be more predictable, it is not devoid of its challenges. The regulatory environment in India is also increasingly becoming tough, especially on higher-risk and imported equipment. The intensity of inspections is growing, and the demands regarding software security and cybersecurity issues are growing. CSDCO usually does not provide a lot of flexibility once the documentation gaps or compliance problems have been discovered, so it is necessary to prepare early.
Practical Reality for Indian Manufacturers
Practically, CDSCO approval tends to provide quick entry into the Indian market, particularly for low and moderate-risk devices. FDA approval, on the contrary, involves higher initial planning, investment, and documentation maturity. Companies that create product designs that are compatible with FDA expectations are usually easier to be in line with CDSCO in the future. The knowledge of these realities aids Indian manufacturers in choosing the appropriate approval strategy and not to underestimate the amount of effort that would be necessary to enter the U.S. market.
CDSCO vs FDA Strategy for Indian Medical Device Companies
To achieve this, a proactive and transparent regulatory approach should be adopted by the Indian manufacturers who are interested in operating in both the local and the U.S. market to ensure delays are kept to a minimum, effort duplication is prevented, and the chances of becoming non-compliant are minimized.
When CDSCO Approval Makes Sense First
Applying the CDSCO approval should be the first approach in the case when the Indian market is an essential target of business, the risk of the device is low or even medium, clinical evidence is small or developing, and time to market is a paramount concern. Under these circumstances, CDSCO offers a quicker and more predictable avenue of early commercialization.
When Should FDA Approval Be Planned Early
When the business model is based on exports, the devices are new or moderate-risk, or the product is software, connectivity, or SaMD intensive, FDA requirements must be planned early. The early alignment of the FDA is highly advantageous to companies with long-term international growth plans because it may prove to be both expensive and time-consuming to retrofit FDA requirements at a later stage.
Best Practice for Dual Compliance
The best approach towards dual compliance is by designing products to the level of FDA as soon as possible. This will involve harmonizing quality systems, documentation practices and risk management processes in both regulatory frameworks. The risk management processes should always be based on ISO 14971, which addresses clinical risk, usability risks, software risk, and cybersecurity risk. Product development should involve cybersecurity and penetration testing, not as an after-approval measure.
A proactive strategy to CDSCO and FDA regulatory mandates will allow the Indian manufacturers to scale up at a faster rate, with less rework, and be compliant in both markets with fewer regulatory surprises.
How Qualysec Supports CDSCO and FDA Compliance for Indian Manufacturers
With the growing number of Indian medical device firms entering the U.S. market, the difference between CDSCO and FDA regulatory requirements is the most visible in terms of cybersecurity expectations. Qualysec assists manufacturers in closing this gap by providing end-to-end FDA cybersecurity support that incorporates both the technical security validation and regulatory documentation.
Qualysec has ventured into medical device firms at both early-stage start-ups and enterprise-level manufacturing, offering support to CDSCO alignment and FDA approval process of medical devices with special emphasis on risk reduction, speed and regulatory confidence.
What Qualysec Delivers for FDA and CDSCO Readiness
FDA penetration testing on any level.
Favors startups, manufacturers who are growing, and large medical devices organizations that are in the pipeline to be reviewed by FDA.
- CDSCO and FDA Cybersecurity validation: Manufacturers of help are brought to meet the changing demands of CDSCO, yet are fully satisfactory to the FDA cybersecurity scrutiny.
- Certified FDA documentation: Produces a submission that is ready with cybersecurity evidence that complies with the FDA guidance and reviewer expectations.
- Support of Emergency FDA submission: Quick service needed by strict FDA schedules, follow-up questions and resubmissions.
- Free compliance gap analysis of FDA: Detects the lapses in cybersecurity and documentation before submission to FDA to avoid delay or refusal.
Qualysec also enables the Indian manufacturers to minimize rework, cut the approval risk, and sustain regulatory confidence in the Indian and U.S. markets by integrating testing of cybersecurity at the early stage.
100% FDA Approval Guarantee
The FDA cybersecurity services of Qualysec are founded on the overall ownership of the process, rather than on disjointed vendor coordination. When the manufacturers are involved with the entire framework of Qualysec, the testing of cybersecurity and documentation is created so as to meet the expectations of the FDA.
This overall accountability will guarantee that evidence on cybersecurity provided to the FDA review is also consistent, defensible, and aligned with the regulatory requirements. The outcome is FDA-ready and one that has confidence to meet the FDA standards.
Qualysec’s End-to-End FDA Cybersecurity Framework
- Start to finish by one partner.
- Regulatory documentation and technical security testing are perfectly matched.
- Full accountability, Qualysec possesses all work.
- Rapid FDA response and no vendor-coordinated delays.
- In-house cybersecurity documentation to in-house FDA approval.
In comparison with multi-vendor strategies that create gaps and delays in the process, Qualysec is a one-stop shop responsible for FDA cybersecurity partner, and thus, Indian manufacturers do not have to juggle CDSCO and FDA compliance at the same time.
Proven FDA Track Record
- Relied on by 20+ companies for successful results with FDA approvals.
- Startup to enterprise manufacturing experience.
- Success in 20+ FDA medical device submissions.
Manufacturers under the Qualysec have the advantage of a framework that has provided effective FDA results, especially for software-connected and enabled medical devices.
Planning FDA approval without complicating CDSCO compliance does not necessarily have to be complicated. Connect with Qualysec experts today and get end-to-end guidance.
FAQs
Q: Can I use my CDSCO approval to get FDA approval faster?
A: No. FDA approval is not directly expedited by the approval of CDSCO. Although certain documents and test data can be duplicated, FDA approval of medical devices needs to be reviewed independently, and includes more technical information, and in many cases, further clinical and cybersecurity evidence.
Q: Which approval should I get first – CDSCO or FDA?
A: It is based on business strategy. If the primary target market is India, pursuing CDSCO approval first is a reasonable approach. However, if the U.S. is a target market or the device software is high-risk or software-driven, it is advisable to plan for FDA requirements early.
Q: Is ISO 13485 certification sufficient for both CDSCO and FDA?
A: Both of them are significant to ISO 13485, but not enough to be FDA-compliant. FDA anticipates further design controls, more documentation, and continuous quality system compliance, not only ISO certification.
Q: Can I use Indian clinical trial data for an FDA submission?
A: Yes, in some cases. Clinical data conducted in India may be admitted by FDA, provided that it is scientifically valid, well-documented, and performed in compliance with the ethical and regulatory standards. Nevertheless, more research can be requested by the FDA.
Q: What are the main reasons Indian devices get rejected by the FDA?
A: Reasons have often been incomplete documentation, poor design controls, the absence of clinical evidence, risk management gaps and the absence of cybersecurity verification, like penetration testing.
Q: How much does it cost to maintain dual compliance annually?
A: Pricing depends on the complexity of devices. Recurring costs can come in the form of audits, post-market surveillance, regulatory changes, cybersecurity testing and quality system maintenance.
Q: Do I need separate manufacturing facilities for CDSCO and FDA?
A: No. The same facility may be available to both markets, but it should satisfy both the regulations of CDSCO and FDA, such as inspection readiness and documentation standards.
Q: What is the role of ISO 14971 in both regulatory systems?
A: Risk management of CDSCO and FDA revolves around ISO 14971. It aids in defining, evaluating and managing the risks of the devices, such as software-related and cybersecurity risks.
Q: Can I sell in the US without FDA approval if I have CDSCO approval?
A: No. CDSCO approval cannot be used without FDA clearance or approval to distribute legally in the U.S. market.
Q: How often do CDSCO and FDA regulations change?
A: Software and cybersecurity FDA guidance and expectations are constantly changing. There is also a changing of the CDSCO rules, whereby there is a tendency to become more aligned to the global norms. Compliance should be managed through constant regulatory monitoring.
Conclusion
In the case of Indian medical device manufacturers, CDSCO vs FDA regulatory needs help to understand how to develop a market strategy applicable and scalable on the global level. Although CDSCO opens the door to the Indian market, the FDA approval requires technical validation at a higher level, more reliable documentation, ongoing post-market management and proper software and cybersecurity risk management focus.
With the increasing software content and interconnectedness of devices, regulators currently anticipate manufacturers to show secure design practices, continued risk management and cybersecurity penetration testing as components of product safety. By synchronizing regulatory, quality, and cybersecurity requirements in the early years, rework will be minimized, and both markets will enhance the chances of compliance in the long term and increase approval in the short term.
Having a track record of experience in the CDSCO engagement and FDA-focused engagements, Qualysec assists Indian manufacturers in integrating FDA penetration testing, guaranteed provision of FDA-ready documentation, and full accountability in the regulatory capacities within a single framework.
0 Comments